Green tea polyphenols inhibit plasminogen activator inhibitor-1 expression and secretion in endothelial cells

Jian Liu1, Chenjiang Ying, Yi Meng

  • 1Department of Nutrition and Food Hygiene, School of Public Health, PR China.

Insights

Green tea polyphenols (GTPs) reduce plasminogen activator inhibitor-1 (PAI-1) in endothelial cells. This pathway may offer cardiovascular protection by inhibiting PAI-1 expression and secretion.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Nutritional Science

Background:

  • Epidemiological studies link green tea consumption to reduced cardiovascular disease risk.
  • Plasminogen activator inhibitor-1 (PAI-1) is implicated in cardiovascular conditions like arteriosclerosis and hypertension.
  • Elevated PAI-1 levels are associated with atherosclerotic lesions and coronary heart disease.

Purpose of the Study:

  • To investigate the effect of green tea polyphenols (GTPs) on PAI-1 expression in endothelial cells.
  • To elucidate the molecular mechanisms underlying GTPs' regulation of PAI-1.
  • To assess the potential of GTPs in cardiovascular disease prevention.

Main Methods:

  • Bovine aortic endothelial cells were treated with varying concentrations and durations of GTPs.
  • PAI-1 expression and secretion were quantified using Western blot and ELISA.
  • The role of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway was examined using wortmannin and Akt activation assays.

Main Results:

  • GTPs significantly decreased PAI-1 expression and secretion in a dose- and time-dependent manner.
  • Inhibition of PI3K with wortmannin reversed the suppressive effect of GTPs on PAI-1.
  • GTP treatment led to increased activation of the protein kinase Akt.

Conclusions:

  • GTPs inhibit PAI-1 expression and secretion in endothelial cells via the PI3K/Akt signaling pathway.
  • This mechanism suggests a potential role for GTPs in cardiovascular protection.
  • Green tea consumption may contribute to managing cardiovascular health by modulating PAI-1 levels.

Related Concept Videos

Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.